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Summary
The authors have provided an in-depth review of the history of saline and silicone gel–filled 
breast implants. In the history of medicine, no devices have been more scrutinized and thor-
oughly studied than breast implants. Although we as plastic surgeons recognize and appreciate 
the benefits that our patients derive from these devices, society as a whole continues to remain 
skeptical. The reasons for this are complex and multifactorial but appear to be fueled by the 
media, oppositional organizations, and several trial lawyers. Prior to 1990, when the silicone 
gel implant controversy began, there were only eight indexed publications that dealt with the 
issue of silicone gel breast implants. Since 1990, there have been more than 500 indexed publi-
cations dealing with silicone gel implants. At the time of the moratorium in 1992, we as plastic 
surgeons did not have a leg to stand on because there was a paucity of scientific evidence to 
support our observations that silicone breast implants were safe and effective devices.
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The female breast has long been an object of both individual and socie-
tal interest. The breast represents a woman’s femininity and sensuality. One 
does not have to look far in the media to recognize the relative value of the 
breast in female perception by society. These factors represent some of the 
underlying motives that have made surgery of the female breast, both aes-
thetic and reconstructive, an area of great interest and a formidable chal-
lenge to plastic surgeons for decades. Arguably, no device or single surgi-
cal procedure has altered the landscape of breast surgery as dramatically as 
prosthetic breast implants. Breast implants have been in use since before the 
mid-1960s, yet the topic still produces heated debate and emotions. Breast 
implants are medical devices designed for surgical implantation to alter the 
size and shape of the breast in women. The principal indications are aesthet-
ic enlargement and reconstruction of breast deformities related to cancer 
treatment, trauma, or congenital abnormalities. Breast implants are manu-
factured filled with either physiologic saline or silicone gel. Each has advan-
tages and disadvantages, but silicone-filled devices are used most commonly 
and generally yield the most natural results. 
Millions of women have had implantation surgery since the introduction 
of silicone gel–filled breast implants more than 40 years ago. It continues 
to be the most popular cosmetic procedure performed by plastic surgeons, 
with more than 300,000 performed annually.1 In the 1990s, sharp controver-
sy arose regarding the health safety of silicone gel–filled breast implants, and 
their use was restricted by the U.S. Food and Drug Administration (FDA) 
in 1992. Ultimately, no evidence was found to support significant safety 
concerns, and the devices were released again for general use in November 
2006.2 Nevertheless, some continue to question the safety of silicone gel 
breast implants, and FDA-mandated postapproval safety studies will be un-
derway through 2018. It is possible that controversy will reemerge as data 
from these studies become available, and patients still need clarification of 
the safety issues involved. 
For these reasons, it is important that plastic surgeons performing breast 
implant surgery understand the fundamental technology behind breast 
1 American Society of Plastic Surgeons (2009), 2008 plastic surgery procedural statistics; 
2009. Available at: http://www.plasticsurgery.org/Media/stats/2008-US-cosmetic-recon-
structiveplastic-surgery-minimally-invasive-statistics.pdf.
2 U.S. Food and Drug Administration. (2009), Silicone gel-filled breast implant timeline, 
Available at: http:// www.fda.gov/ MedicalDevices/ ProductsandMedicalProcedures/ 
ImplantsandProsthetics / BreastImplants/UCM064461.
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implants and be familiar with all the safety issues. Patients and others in 
their local communities will expect them to be experts. This paper reviews 
the fundamentals of silicone chemistry, the history of breast implantation 
surgery and regulation, and current knowledge about safety and efficacy. 
The purpose is to equip the practitioner to hold a well-informed opinion 
about silicone gel breast implants, to be able to answer common questions 
about the use of breast implants and to work with their patients to make 
sound clinical decisions about breast implantation surgery.
Silicone
Silicone refers to a family of compounds with a molecular backbone of 
alternating silicon (Si) and oxygen (O) atoms. Silicon is a semimetallic ele-
ment found in nature as silica (SiO2), the most abundant substance on Earth, 
commonly found in nature in the sand and quartz-containing rocks. Silicon 
is located just below carbon on the periodic table and therefore has similar 
chemical behavior, most notably the ability to form long-chain molecules 
called polymers. The basic repeating unit (monomer) of the silicone polymer 
is siloxane (R2SiO), named because it contains silicon, oxygen, and alkane 
(saturated hydrocarbon) side groups. The most common formulation used in 
medicine is poly(dimethylsiloxane) (PDMS), in which the siloxane monomer 
carries two methyl (—CH3) groups.
The hydrosilation reaction is catalyzed by small amounts of platinum. 
Small amounts of residual platinum may be detected in the final product.3 
Some forms of platinum have immunogenic potential, and the possibility of 
this as a source of adverse reactions to silicone gel breast implants has been 
suggested. However, no clinical report has positively related the trace plati-
num found in breast implants to human disease, and the type and quantity 
of platinum used in manufacturing provide no biologically plausible ratio-
nale for health problems from this cause.4,5 Silicone-based medical devices 
have been in use since the late 1950s.6
In plastic surgery, silicone devices have been used in a wide variety of 
clinical applications. Silicone implants are used to augment the craniofacial 
3 Maharaj SV. (2007), Exposure dose and significance of platinum and platinum salts in 
breast implants. Arch Environ Occup Health; 62(3), 139–146.
4 Wixtrom RN. (2007), Silicone breast implants and platinum. Plast Reconstr Surg;120(7 
suppl 1), 118S–122S.
5 Bondurant S, Ernster V, Herdman R, eds. (2000), Silicone breast implants and cancer. In: 
Safety of Silicone Breast Implants. Washington, DC: National Academy Press, 233–241.
6 Costantino PD.(1994), Synthetic biomaterials for soft-tissue augmentation and replace-
ment in the head and neck. Otolaryngol Clin N Am;27(1), 223–262.
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skeleton and reconstruct the orbital floor. They are used in hand surgery for 
joint reconstruction, flexor tendon replacement, and bone block spacers. 
Little controversy has surrounded the use of silicone for these applications. 
The application that has generated the most controversy is breast implanta-
tion surgery.
It is important to keep in mind that the majority of silicone gel is sili-
cone oil within the confines set by the PDMS gel matrix. The ratio of silicone 
liquid to gel is controlled by manufacturers to control the viscosity of the 
gel. Elastomers of silicone have high degrees of cross-linking and almost no 
PDMS oil. Breast implant shells, both silicone and saline filled, consist of 
a vulcanized silicone elastomer that is reinforced with silica for increased 
strength.7 In an effort to reduce gel bleed from silicone-filled devices, phe-
nyl or trifluoropropyl groups are bonded to the shell to decrease the shell 
permeability to PDMS oil.8,9 These “low-bleed” implant shells with “barrier 
coating” are characteristic of the current third-, fourth-, and fifth- genera-
tion implants.
History of manufacturing and materials
Prior to the development of prosthetic breast implants, numerous materi-
als were put on trial for the purpose of augmenting the female breast. Until 
the 1950s, materials included autogenous fat and dermal grafts, fat injections, 
paraffin injections, and insertion of glass balls, ivory, rubber, and Terylene 
wool.10,11 These materials frequently led to infection, tissue necrosis, and 
firmness of the breast. The autogenous materials were uniformly troubled 
by resorption. The 1950s and 1960s saw the use of many other products.
The development of the silicone gel prosthesis in 1962 marked an im-
portant new era in breast surgery. Since Cronin and Gerow first reported 
its use, few other materials have been used for breast augmentation. This is 
partly due to the success of silicone devices and also the subsequent FDA 
7 Brody GS.(1997), On the safety of breast implants. Plast Reconstr Surg, 100, 1314
8 Barker DE, Retsky MI, Schultz SL.(1981), The new low bleed mammary prosthesis: an ex-
perimental study in mice. Aesthetic Plast Surg,5, 85.
9 Caffee HH.(1986), The influence of silicone bleed on capsular contracture. Ann Plast 
Surg, 17, 284.
10 Bondurant S, Ernster V, Herdman R, eds. (2000), Safety of Silicone Breast Implants. 
Washington, DC: National Academy Press.
11 Young VL, Watson ME. (2001), Breast implant research: where we have been, where we 
are, where we need to go. Clin Plast Surg, 28(3), 451.
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regulation of medical devices that started shortly after the development of 
silicone gel devices.12
Currently available breast implants are made of a silicone elastomer shell 
filled with either physiologic saline solution or silicone gel. Each has advan-
tages and disadvantages. Saline filled devices can be adjusted to optimum 
size at the time of implantation, but they can be unnaturally firm, form vis-
ible wrinkles on the breast surface, and move less naturally with changes 
in body position. Silicone gel–filled implants overcome these disadvantages 
because they simulate the density of natural human tissue. They are partic-
ularly useful when there is a small amount of overlying soft tissue as in the 
augmentation of very small breasts or breast reconstruction.
The manufacturing process of breast implants, as of all medical devices, 
is a tightly regulated process that must meet rigid quality assurance criteria. 
Surprisingly, the majority of breast implant shells are produced individually 
through a handmade process. Shells are produced through repeated dipping 
of mandrels into liquid silicone dispersion that is then cured with heat or hu-
midity. After the silicone shell is cured, it may be removed from the mandrel, 
inspected for irregularities, and measured to ensure precise compliance with 
thickness standards. Shells are filled with their appropriate silicone gel and 
sealed with a patch bonded to the surface. Saline-filled devices have a valve 
incorporated into the shell to allow the filling of the device in vivo.
Implant generations
When the generation scheme was first proposed, there were essentially 
three generations of breast implants corresponding to products developed 
in the 1960s (first generation), 1970s (second generation), and 1980s (third 
generation). First-generation devices are represented by the original silicone 
gel implant developed by Cronin and Gerow. This device, the Silastic 0, 
was manufactured by Dow Corning from approximately 1964 to 1968. The 
Silastic 0 possessed a thick elastomer shell with seams and a viscous sili-
cone gel. Dow Corning made several modifications to the original device, 
including changes in the elastomer, creating a seamless shell, and later made 
the shell much thinner. First-generation devices overall were characterized 
by thick shells, a thick viscous gel, and Dacron patches, and were produced 
12 Cronin TD, Gerow FJ. (1963), Augmentation mammaplasty: a new “natural feel” prosthe-
sis. In: Transactions of the Third International Congress of Plastic Surgery. Amsterdam, 
Netherlands, 41.
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until the late 1970s. The most commonly reported complication of these de-
vices was a capsular contracture. 
Second-generation devices were modified in an attempt to improve the 
rate of capsular contracture. These devices were designed with a much thin-
ner shell (0.13 mm versus 0.25 mm average thickness) and a less viscous gel, 
and the Dacron patches were removed.11 The first second-generation device 
was Dow Corning’s Silastic I. It was introduced in 1972, and the manufac-
turing of the Silastic I overlapped with the production of Silastic 0. Silastic I 
was produced until 1986. It did not provide any appreciable reduction in the 
incidence of capsular contracture and reportedly had a higher incidence of 
rupture that was attributed to the strength of its shell.11
Gel bleed is the diffusion of non–cross-linked silicone oil from the gel 
across the elastomer shell into the surrounding environment. Although the 
significance of this phenomenon remains unclear, it stimulated manufactur-
ing changes that are characteristic of third-generation devices. Thicker, rein-
forced barrier shells characterize third-generation devices. 
The thickness and strength improvements were developed out of con-
cern for shell failure with second-generation devices. Shell strength was 
improved by reinforcing the elastomer composition with silica.7 Creating a 
barrier to gel diffusion with phenyl or trifluoropropyl groups bonded to the 
shell surface reduced diffusion of non–cross-linked silicone.8,9 These prop-
erties are retained in current manufacturing processes. It is important to 
keep in mind that gel bleed is a function of diffusion of silicone oil across the 
elastomer. The gel bleed does not change based on the viscosity (degree of 
cohesion of the gel filler).
Saline-filled breast implants were first manufactured in France in 1964, 
introduced by Arian with the goal of being surgically placed via smaller in-
cisions. These devices had a high failure rate and were discontinued in the 
early 1970s.11 HeyerSchulte was the first U.S. manufacturer of saline-filled 
devices. The original devices consisted of thin shells created through a 
high-temperature vulcanization (HTV). These devices were prone to spon-
taneous deflation.11 Modifications in shell manufacturing have allowed high 
success rates that characterize modern saline-filled devices. The current de-




Modifications in the characteristics of the implant filler have also oc-
curred. The most obvious is the change to saline-filled devices during the 
“implant crisis.” However, significant modifications have occurred in the 
silicone gel characteristics. The modifications in silicone gel technology are 
significant enough that many consider the modern era gels to be the fourth 
implant generation. Since 1992, due to increased demands to improve man-
ufacturing processes, silicone gel implants have been improved devices with 
slightly thicker shells and more cohesive gel filler than third-generation 
devices. 
Because breast implants are filled with medical-grade silicone, changes 
in silicone gel chemistry have centered on the cohesive quality of the gel. 
All silicone gels are cohesive, but the degree of cohesiveness has clinical 
importance. The degree of cohesiveness is a reflection of the elastic mem-
ory or shape retention of the gel. Cohesiveness is produced by the chemi-
cal cross-linking of the silicone gel molecules. The degree of cohesiveness 
imparts important characteristics to the structure and feel of the implant. 
Second-generation implants produced before 1985 contained minimally co-
hesive gels. Third- and fourth-generation devices evolved to contain increas-
ingly cohesive gels after 1985, and in 1993, form-stable cohesive gel implants 
were introduced.
The fifth-generation implants are form-stable cohesive gel implants (e.g., 
Inamed 410 and Mentor CPG). These are shaped silicone gel devices with en-
hanced cohesion that offer improved breast shaping and results. These im-
plants are currently undergoing clinical trials in the United States. Silicone 
gel and saline are the only materials presently available for use as filling ma-
terial for breast implants in the United States. Soy-filled implants (Trilucent) 
were marketed for a short time period in Europe but were voluntarily pulled 
from the market in 2000 by the manufacturer.13,14 Trilucent implants con-
tained Trilipid 6, a medical-grade triglyceride fat extracted from soybean oil. 
This material was studied in animals and not shown to be a safety concern. 
Approximately 5,000 European women and 50 U.S. women received the 
implants as part of European and U.S. clinical trials. In the United States, 
the devices had limited availability through an investigation device exemp-
tion. The devices were taken out of clinical use due to the development of 
13 Barnett MP. (1997), Triglyceride-filled breast implants. Plast Reconstr Surg, 99, 2105.
14 Rizkalla M, Duncan C, Mathews RN. (2001), Trilucent breast implants: a 3-year series. Br 
J Plast Surg, 54, 125.
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inflammatory reactions resulting from the leakage of the oil into the sur-
rounding tissues.15,16 The reactions resolved with the removal of the devices 
and did not present long-term health concerns. There are presently no other 
alternative fillers available through a clinical trial.
Surface texture
Surface texturing of silicone implants was first performed in the late 
1960s, with the goal of preventing capsular contracture.11 Polyurethane-
coated implants were introduced at this time but not popularized until the 
1980s. Polyurethane devices were demonstrated to significantly lower the in-
cidence of contracture, but two main concerns led to their discontinuation. 
Polyurethane was shown to undergo a degradation process in vivo that pro-
duced toluene diamine. 17,18
Currently, two different textured silicone elastomer shells are available 
from Mentor Corporation and Inamed. Mentor was the first to receive FDA 
approval for its textured shell. The Siltex pattern is created as a negative con-
tact imprint of a texturing foam. This produces many fine nodules on the 
surface of the shell in a regular distribution. The size of these nodules ranges 
from 40 to 100 m in height and from 70 to 150 m in width.19 Inamed’s Biocell 
surface is produced through a lost salt technique. The implant shell is coated 
with finely graded salt under light pressure. The salt crystals are subsequent-
ly lost through the manufacturing process, leaving many fine depressions on 
the surface of the shell. These pores range from 600 to 800 m in diameter and 
from 150 to 200 m in height.19
In regard to silicone gel implants, both surface textures have been shown 
to have benefits in improving the rate of capsular contracture, but this effect 
has not been realized in association with saline-filled devices, and therefore 
a universal benefit has not been demonstrated.11 The texturing also provides 
adhesiveness of the implant to the surrounding tissue. This is an extremely 
15 Choudhary S, Cadier MAM, Cottrell BJ. (2000), Local tissue reactions to oil-based breast 
implant bleed. Br J Plast Surg, 53, 317.
16 Papanastasiou S, Odili J, Newman P, et al. (2000), Are triglyceride breast implants really 
biocompatible? Ann Plast Surg, 45, 172.
17 Young, V.L. (2001) ,451. Sinclair TM, Kerrigan CL, Buntic R. (1993) Biodegradation of the 
polyurethane foam covering of breast implants. Plast Reconstr Surg, 92, 1003.
18 Benoit FM. (1993), Degradation of polyurethane foams used in the Meme breast implant. J 
Biomed Mater Res, 27, 1341.
19 Danino AM, Basmacioglu P, Saito S, et al. (2001), Comparison of the capsular response 
to the Biocell RTV and Mentor 1600 Siltex breast implant surface texturing: a scanning 
electron microscopic study. Plast Reconstr Surg, 108(7), 2047.
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important consideration with shaped devices to prevent rotation and for cer-
tain considerations in breast reconstruction. Increased fold flaw failure11,20 is 
a theoretical concern with a nonmobile device. When a device is not allowed 
to rotate, the natural folds in the elastomer shell do not cycle, and fatigue 
of the fold and subsequent failure may occur; however, this has not been 
demonstrated scientifically.
Breast implants are widely used, the cosmetic industry is growing, and 
there are valuable lessons to learn from countries that have experienced 
their own regulatory crises. Here are absolutely vital lessons to learn from 
governments, regulators, and the professions in Europe.21 
PIP implant has a rupture rate disproportionately higher than equivalent 
devices and reawakens the debate for a more robust implant registry than a 
system of voluntary reporting.22
Recent implant crises have highlighted the need for robust registries. It 
is important to foster international collaboration from the outset to avoid 
duplication of efforts and enable the development of effective international 
early warning systems.23
Breast augmentation remains one of the most common aesthetic proce-
dures performed worldwide. Silicone implants have undergone an evolution 
with the availability of both fourth- and fifth-generation devices. Clinicians 
should strive to provide ongoing data and sound science to continue to im-
prove clinical outcomes in the future.24
Most of the current generation devices have been extensively studied, 
and are deemed safe and efficacious with reasonable aesthetic outcomes and 
acceptable morbidity. Nevertheless, the shape, feel, safety, and longevity of 
these devices remain important areas of continuing research. Healthcare 
providers should be encouraged to provide ongoing robust scientific data 
20 Brandon HJ, Young VL, Jerina KL, et al. (2001), Scanning electron microscopy character-
ization of surgical instrument damage to breast implants. Plast Reconstr Surg;108(1):52.
21 Silicone breast implants: lessons from the USA(2012), The Lancet, Editorial, Vol 379, is-
sue 9811, P93.
22 Berry MG, et al. (2012), The PIP mammary prosthesis: a product recall study. J Plast 
Reconstr Aesthet Surg. 2 Vol 65, Issue 6, 697–704.
23 Cooter RD, et al. (2015), International importance of robust breast device registries. Plast 
Reconstr Surg.;135(2):337-8.
24 Maxwell G., A. Gabriel, The Evolution of Breast Implants. Plastic and Reconstructive 
Surgery. 134(1S):12S–17S, July 2014.
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along with new ideas for improvement of the existing devices to enhance 
results and provide the best possible outcome for the patients.25
In summary, there have been five generations of breast implants since 
their inception in the early 1960s. These generations are based on character-
istics of the shell, characteristics of the filler, shape, and surface configura-
tion. The clinical behavior of a given implant may be based on its respective 
generation.
Conclusion
Breast implant technology has advanced significantly since the mid-
1960s. Introduced by Cronin and Gerow in 1962, silicone gel breast implants 
redefined the modern era of breast augmentation. It is important to keep 
in mind that those current implants, both silicone, and saline, are signifi-
cantly better devices than earlier-generation devices. Future advances in im-
plant technology are inevitable. Ongoing trials in the United States include 
form-stable cohesive gel implants, which comprise the next (fifth) generation 
of silicone gel implants. Long-term results from Europe and Brazil (Inamed 
410 and Mentor CPG) are unparalleled, and early investigation device ex-
emption results in U.S. clinical trials are promising. There is no doubt that 
implant technology will allow surgeons to use proper patient analysis and 
technique superior results in the future. The scientific evidence that we have 
today clearly supports the fact that silicone gel–filled breast implants are safe 
and effective. These scientific studies are reproducible, and there is no rea-
son to suspect that future studies will not come to the same conclusions.
25 C. Kaoutzanis; J. Winocour; J. Unger; A. Gabriel; P. Maxwell;(2019), The Evolution of 
Breast Implants, Seminars in Plastic Surgery, 33(4), 217–223.
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Sažetak
Autori daju širok pregled povijesti silikonskih implantata za dojke punjenih fiziološkom oto-
pinom i silikonskim gelom. U povijesti medicine niti jedna vrsta implantata nije bila toliko 
pomno i temeljito proučavana kao implantati za dojke. Iako plastični kirurzi prepoznaju i 
cijene koristi koje pacijentice imaju od ovih vrsta implantata, društvo u cijelosti ne prestaje 
biti skeptično. Razlozi za to su kompleksni i multifaktorijalni, ali čini se da su uveličavani od 
medija, nekih organizacija, pa čak i lobija odvjetnika. Do 1990., kada su započele polemike 
oko silikonskih implantata za dojke, tek se osam članaka u indeksiranim časopisima bavilo 
tom temom, a 1990. do danas objavljeno ih je više od 500. U vrijeme moratorija 1992. plastič-
ni kirurzi nisu imali čvrstog uporišta zbog nedostatka znanstvenih dokaza koji bi podržavali 
stajalište da su silikonski implantati za dojke sigurni i djelotvorni.
Ključne riječi: silikonski implantati za dojku, punila za implantat, tekstura površine
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